The Nephritis Associated with Viral Infections

Akihiko Numata, Yoshiyuki Morishita* and Eiji Kusano
Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Abstract
Renal involvement associated with various viruses has been identified, with each associated with a different disease type. Accumulated studies have revealed the pathogenesis and optimal therapies of nephritis associated with viral infections. This review focuses on the nephritis associated with viral infections.

Introduction
Renal involvement associated with several viruses has been identified, with each associated with a different disease type. The pathogenesis and optimal therapies of renal involvement associated with virus infections have been increasingly understood through previous studies.

The mechanism of renal involvement by virus infections
The mechanism of development of renal involvement associated with viral infections can be categorized into those by direct effects of renal parenchymal infection and those by immune response to extra renal infection [1]. In the former type, renal injury is caused by cytomegalovirus, herpes simplex virus, adenovirus, hantavirus, BK virus, a part of human immunodeficiency virus (HIV). In this type, direct toxicity of viruses and/or antibody (Ab) reactions against antigens (Ag) of viruses that infect the kidney causes renal injury [2,3]. The latter type of renal injury is caused by hepatitis B virus (HBV), hepatitis C virus (HCV), a part of HIV and parvovirus B19. In this type, the depositions of Ag-Ab complexes called immune complexes, which are produced in the extra renal space by Ab reactions against Ag of the virus, cause renal injury [2,3].

HBV-associated nephritis
HBV is transmitted through human blood and body fluids. HBV infection may cause not only hepatitis, but also a variety of renal diseases, including membranous glomerulonephritis (MN), membranoproliferative glomerulonephritis (MPGN) and polyarteritis nodosa [4,5]. MN associated with HBV infection, which often causes nephritic syndrome, has been reported most frequently. It has been proposed that the deposition of HBe Ag and anti-HBe Ab complex is responsible for the formation of pathogenic subepithelial immune deposits [6]. Through the serum conversion from HBe Ag to anti-HBe Ab, spontaneous resolution of nephritis is most common in infantile cases; however, it is relatively uncommon in adults [5,7,8]. MPGN associated with HBV infection has also been reported. The deposition of circulating HBe Ag or HBs Ag-anti HBs Ab complexes in the mesangial area and subendothelial space characterizes the MPGN associated with HBV infection [6]. Corticosteroids and other immunosuppressants have been used as the basic treatment for HBV-associated nephritis [9]; however, there is little consensus about the optimal choice of such agents for the treatment of HBV-associated nephritis among HBsAg carriers, since the treatment might enhance viral replication and precipitate hepatic flares due to reactivation of hepatitis [10-13]. The use of antiviral drugs and interferon has also been reported for the treatment of HBV-associated nephritis; however, there are limited data on this. Interferon therapies have less resistance, but may be indicated in younger patients with normal renal function because of side effects such as fever, listlessness, myalgia and depression. Conjeevaram et al. [14] reported that 15 HBV-associated nephritis patients were treated by interferon-α therapy and 8 patients had a long-term serological response with sustained loss of serum HBe Ag and HBV DNA, and 7 of 8 of those patients also showed marked improvement in proteinuria [14]. Tang et al. reported that lamivudine treatment improves renal outcome in HBV carriers with MN [15].

HCV-associated nephritis
Various types of glomerular nephritis such MN, Focal Segmental Glomerulosclerosis (FSGS), proliferative glomerulonephritis and fibrillary and immunotactoid glomerulopathies have been recognized as being associated with HCV infection [16-19]. The deposition of HCV Ag – anti-HCV Ab complexes in the glomerulus is thought to be responsible for HCV-associated nephritis [20]. In addition, the deposition of mixed cryoglobulin, which is characterized by monoclonal immunoglobulin (IgMκ) and polyclonal immunoglobulin (IgG), produced in association with HCV infection in the glomerulus occasionally causes nephritis. MPGN is most frequently observed by the deposition of mixed cryoglobulin.

Antiviral therapy with interferon alpha or pegylated interferon has been reported to be effective for HCV-associated nephritis [19]. Johnson et al. [19] reported that 6 to 12 months of interferon alpha treatment was effective for HCV-associated MPGN with or without cryoglobulinemia in 14 patients. In this study, proteinuria was decreased in association with the disappearance of HCV RNA from the plasma [19]. In addition, an anti-viral drug, ribavirin, improves the sustained virologic clearance when given in combination with interferon. Alric et al. [21] reported that 12 of 18 patients showed improved HCV-associated glomerulonephritis associated with HCV RNA clearance (sustained virologic response) by the combination therapy of regular or pegylated interferon alpha and ribavirin. Recently, the effectiveness of therapy with rituximab, which is a chimeric monoclonal Ab against the protein CD20, for HCV-associated mixed cryoglobulinemia has been reported [22].

HIV-associated nephritis
FSGS is a relatively common complication in patients infected with HIV; however, an increasing number of different forms of renal disease...
such as MN, MPGN, amyloidosis, interstitial nephritis and thrombotic thrombocytopenic purpura have been observed [23-25]. The severity of nephritis is a critical factor for mortality and worse outcomes in HIV-infected patients [26,27]. The mechanism of HIV-associated nephritis has not been fully revealed. The deposition of HIV Ag – anti-HIV Ab complexes in the glomerulus is thought to contribute to the development of HIV-associated nephritis. Although HIV is considered to be able to infect glomerular endothelial cells, mesangial cells or tubular cells, it has not been well determined whether HIV itself plays a direct role in the development of renal injury [28-30]. Studies on animal models suggested that cytokines such as fibroblast growth factor and transforming growth factor-beta may play a role in the matrix accumulation, fibrosis and tubular injury associated with HIV-associated nephritis [31,32]. Therapy with a combination of antiretroviral drugs, typically three or four, known as highly active anti-retroviral therapy (HAART), has been thought to be effective for HIV-associated nephritis. Schwartz et al. [33] reported that HAART reduced the rate of progression from HIV-associated nephritis to end-stage renal disease. Lucas et al. [34] reported that HAART may prevent the development of HIV nephritis. ACE inhibitors may also have beneficial effects for HIV-associated nephritis in terms of proteinuria and long-term renal survival [35,36]. Corticosteroids or other immunosuppressants have been considered for treatment of HIV-associated nephritis [37,38].

**Human parvovirus B19-associated nephritis**

Glomerulonephritis associated with parvovirus B19 infection has been reported, and most of these cases are in females. The deposition of human parvovirus B19 Ag – anti-human parvovirus B19 Ab complexes in the glomerulus is thought to be responsible for human parvovirus B19-associated nephritis. Histological examinations of the kidney demonstrated endocapillary proliferative glomerulonephritis in most cases and spontaneous resolution is commonly observed. In several cases, the involvement of parvovirus B19 has been proven by immunohistochemistry or by detecting parvovirus B19 DNA from renal biopsy specimens [39,40].

**Hantavirus-associated nephritis**

Hantavirus-associated nephritis showed proteinuria, hematuria and reduced renal function. The most prominent renal histopathologic change is acute tubulointerstitial nephritis [41]. The mechanism of the renal involvement is considered to be not only damage to endothelium by the virus, but also damage to tubulointerstitium by cytokines [42,43]. However, the clinical course can be extremely variable and some infected patients are asymptomatic, while some patients with severe cases progress to shock and oliguric acute renal failure sequentially from fever with hemorrhage [44]. Although some patients may have persistent proteinuria or hypertension, most recover kidney function without any specific drug [44].

**BK virus-associated nephritis**

BK virus infection causes tubulointerstitial nephritis and ureteral stenosis in renal transplant recipients [45]. The mechanism of renal involvement by BK virus is considered to involve direct damage to infected urothelium of BK virus [45]. An increased incidence of BK virus infections in renal transplant recipients is associated with an increased degree of immunosuppression [45]. The clinical features of BK-associated nephritis most closely resemble those of acute rejection, which may be accompanied by fever [46-49] (Table 1).

**Other virus-associated nephritis**

Many other viruses such as cytomegalovirus, herpes simplex virus

---

**Table 1:** The nephritis with viral infections.

| Virus                  | Disease type                        |
|------------------------|-------------------------------------|
| HCV                   | MN                                  |
| BK virus               | MGBP (mixed cryoglobulin)           |
| HIV                   | FSGS, MN, MPGN, tubulointerstitial nephropathy |
|                       | amyloidosis, TTP                    |
| Human parvovirus B19  | endocapillary proliferative glomerulonephritis |
| Hantavirus             | tubulointerstitial nephritis        |
| BK virus               | tubulointerstitial nephritis        |

Table 1. The nephritis with viral infections.

and adenovirus may also cause renal involvement by a direct or indirect mechanism.

**Conclusion**

Various virus infections cause several types of nephritis. Several drugs have been reported to be effective for treatment of virus infection-associated nephritis. However, the choice of drugs as well as their use in the treatment of virus infection-associated nephritis has to be carefully determined considering the possibility that those drugs may exacerbate renal damage. Further studies are still needed to confirm the mechanism and treatment of virus infection-associated nephritis.

**References**

1. Ronco P (1982) Viruses and Glomerulonephritis. Nephron 31: 97-102.
2. Cacallo T (1998) Tubulointerstitial nephritis. Heptinstall’s Pathology of the Kidney 6th Edn 321-396.
3. Nadasdy T (2007) Acute postinfectious glomerulonephritis and glomerulonephritis caused by persistent bacterial infection. Heptinstall’s Pathology of the Kidney Sixth Edition 321-396.
4. Johnson RJ, Couser WG (1990) Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 663-676.
5. Lai KN, Lai FM (1991) Clinical features and the natural course of hepatitis B virus-related glomerulonephritis. Kidney Int Suppl 35: 40-45.
6. Takekoshi Y, Tochimaru H, Nagata Y, Itami N (1991) Immunopathogenetic mechanisms of hepatitis B virus-related glomerulonephritis. Kidney Int Suppl 35: 34-39.
7. Lai KN, Philip KT, Lui SF, Tak CA, Jhon SL, et al. (1991) Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324: 1457-1463.
8. Lin CY (1995) Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 47: 225-230.
9. Ponticelli C (2007) Membranous nephropathy. J Nephrol 20: 268-287.
10. Lai KN, Tam JS, Lin HJ, Lai FM (1990) The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenemia. Nephron 54: 12-17.
11. Tang S, Lai FM, Lui YH, Tang CS, Kung NN, et al. (2005) Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68: 1750-1758.
12. Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, et al. (2006) Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65: 423-426.
13. Akimoto T, Otake T, Tanaka A, Takahashi H, Higashihizawa T, et al. (2011)
Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases. Clin Exp Nephrol 15: 289-293.

14. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, et al. (1995) Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 109: 540-546.

15. Tang S, Lai FM, Lui YH, Tang CS, Kung NN, et al. (2005) Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68: 1750-1758.

16. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, et al. (1994) Renal manifestations of hepatitis C virus infection. Kidney Int 46: 1255-1263.

17. Johnson RJ, Gretich DR, Yamabe H, Hart J, Bacchi CE, et al. (1993) Membranous proliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465-470

18. Cosio FG, Roche Z, Agarwala A, Falkenhain ME, Sedmak DD, et al. (1996) Prevalence of hepatitis C in patients with idiopathic glomerulonephritis in native and transplant kidneys. Am J Kidney Dis 28: 752-759.

19. Johnson RJ, Gretich DR, Couser WG, Alpers CE, Wilson J, et al. (1994) Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46: 1700-1704.

20. Sansono D, Gesualdo L, Manno C, Schena FP, Dammacco F (1997) Hepatitis C virus-related proteins in kidney tissue from hepatitis C infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25: 1237-1244

21. Arlt L, Plaisier E, Thebault S, Peron JM, Rostaing L, et al. (2004) Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MNP. Am J Kidney Dis 43: 617-623.

22. Rocciattolo D, Baldovino S, Rossi D, Mansouri M, Naretto C, et al. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 19: 3054-3061.

23. Szczeczen LA, Gupta SK, Habash R, Guasch A, Kalayjian R, et al. (2004) The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66: 1145-1152.

24. Parkhie SM, Fine DM, Lucas GM, Altta MG (2010) Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 5: 788-804.

25. Berggren R, Batuman V (2005) HIV-associated renal disorders: recent insights into pathogenesis and treatment. Curr HIV/AIDS Rep 2: 109-115.

26. Szczeczen LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, et al. (2004) Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 39: 1199-1206.

27. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, et al. (2005) Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16: 2412-2420.

28. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appliah KA, et al. (2004) Highly active antiretroviral therapy and the epidemic of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541-546.

29. Burns GC, Paul SK, Toth IR, Sivak SL (1997) Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8: 1140-1146.

30. Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, et al. (2003) Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 64: 1462-1471.

31. Ingulli E, Tejani A, Fikrig S, Nicastri A, Chen CK, et al. (1991) Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 119: 710-716.

32. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, et al. (1994) Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 101: 41-48.

33. Komatsuda A, Ohtani H, Nimura T, Yamaguchi A, Wakui H, et al. (2000) Endocapillary proliferative glomerulonephritis in a patient with parvovirus B19 infection. Am J Kidney Dis 36: 851-854.

34. Nakazawa T, Tomosugi N, Sakamoto K, Asaka M, Yurui T, et al. (2000) Acute glomerulonephritis after human parvovirus B19 infection. Am J Kidney Dis 35: E31.

35. Mustonen J, Helin H, Pietila K, Brummer-Korvenkontio M, Hedman K, et al. (1994) Renal biopsy findings and clinicopathologic correlations in nephropathia epidemicica. Clin Nephrol. 41: 121-126

36. Temonon M, Mustonen J, Helin H, Pasternack A, Vaheri A, et al. (1996) Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemicica kidneys: an immunohistochemical study. Clin Immunol Immunopathol 78: 47-55.

37. Mäkelä S, Mustonen J, Ala-Houhala I, Hurme M, Kolivisto AM, et al. (2004) Urinary excretion of interleukin-6 correlates with proteinuria in acute Puamula hantavirus-induced nephritis. Am J Kidney Dis 43: 809-816.

38. Miettinen MH, Makela SM, Ala-Houhala IO, Huhtala HS, Koobi T, et al. (2006) Ten-year prognosis of Puamula hantavirus-induced acute interstitial nephritis. Kidney Int 69: 2043-2048.

39. Binet I, Nickeleit V, Hirsch HH, Prince O, Dalquen P, et al. (1999) Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 67: 918-922

40. Randhawa PS, Finkelstein S, Scantlebury V, Shaprio R, Vivas C, et al. (1999) Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67: 103-109.

41. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, et al. (2002) Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13: 2145-2151.

42. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, et al. (2005) BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 68: 1834-1839.

43. Gall A, Hariharan S (2008) BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2: 68-75.